

WHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET

*This patient information leaflet focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities.**

The medicine may be authorised for additional or different uses by national medicines regulatory authorities.

* https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification_Feb2017_newtempl.pdf

Information for the patient

[HA765 trade name][†]
Dolutegravir

*The warnings and instructions in this leaflet are intended for the person taking the medicine.
If you are a parent or carer responsible for giving the medicine to someone else such as a child,
you will need to apply the instructions accordingly.*

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have questions about the medicine, ask your health care provider.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness seem to be the same as yours.
- If you are concerned about any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What [HA765 trade name] is and what it is used for
2. What you need to know before you take [HA765 trade name]
3. How to take [HA765 trade name]
4. Possible side effects
5. How to store [HA765 trade name]
6. Contents of the pack and other information

1. What [HA765 trade name] is and what it is used for

[HA765 trade name] contains the active ingredient dolutegravir. Dolutegravir belongs to a group of antiretroviral medicines called integrase inhibitors.

[HA765 trade name] is used to treat HIV (human immunodeficiency virus) infection in children at least 4 weeks of age or older and weighing at least 3 kg. It is always used in combination with other antiretroviral medicines (combination therapy).

[HA765 trade name] does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. Reducing the amount of virus helps to increase the number of white blood cells, called CD4 cells, that are important for fighting infection.

[HA765 trade name] does not work equally well in everybody. Your health care provider will check how well your treatment is working.

To control your HIV infection, and to stop your illness from getting worse, you must take all your HIV medicines regularly, unless your health care provider tells you to stop taking any.

This product is intended for use in children. Safety information on use in adults is also provided.

2. What you need to know before you take [HA765 trade name]

Don't take [HA765 trade name] if you are:

- allergic to dolutegravir or any of the other ingredients of this medicine (listed in section 6)
- taking another medicine called dofetilide (to treat heart conditions) or fampridine (also known as dalfampridine, used in multiple sclerosis).

[†] Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

If you think any of these apply to you, tell your health care provider.

Warnings and precautions

Look out for important symptoms

Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:

- infections and inflammation
- joint pain, stiffness and bone problems

You need to know about important signs and symptoms to look out for while you're taking [HA765 trade name].

Read the information, 'Other possible side effects' in Section 4 of this leaflet.

Protect other people

HIV infection is spread by sexual contact, or by transfer of infected blood (for example, by sharing injection needles). You can still pass on HIV when taking this medicine, but the risk is lowered by effective antiretroviral therapy. Discuss with your health care provider the precautions needed to avoid infecting other people.

Children

There is not yet enough information to recommend the use of dolutegravir in children weighing less than 3 kg.

Other medicines and [HA765 trade name]

Tell your health care provider if you are taking, have recently taken or are planning to take any other medicines. This includes medicines that you buy without a prescription and herbal medicines.

You **must not** take [HA765 trade name] with dofetilide, which is used to treat heart conditions or fampridine (also known as dalfampridine), used in multiple sclerosis.

Some medicines can affect how [HA765 trade name] works or increase side effects. [HA765 trade name] can also affect how some other medicines work.

Tell your health care provider if you are taking any of the following:

- metformin, to treat diabetes
- antacids, to treat indigestion and heartburn (see section 3)
- calcium supplements, iron supplements and multivitamins (see section 3)
- etravirine, efavirenz, fosamprenavir/ritonavir, nevirapine or tipranavir/ritonavir, to treat HIV infection
- rifampicin, to treat tuberculosis and other bacterial infections
- phenytoin and phenobarbital, to treat epilepsy
- oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder
- St John's wort (*Hypericum perforatum*), a herbal remedy used for treating depression

If you are taking any of these, your health care provider may adjust your dose or arrange extra check-ups.

Pregnancy

If you are pregnant, if you become pregnant, or if you are planning to have a baby talk to your health care provider about the risks and benefits of taking [HA765 trade name].

Taking [HA765 trade name] around the time you become pregnant or during the first weeks of pregnancy may slightly increase the risk of a birth defect called neural tube defect (e.g. spina bifida).

Do not stop taking [HA765 trade name] without checking with your health care provider, as this may harm you and your unborn baby.

Breast-feeding

If you wish to breast-feed your baby, you should discuss the risks and benefits with your health care provider.

Driving and using machines

[HA765 trade name] can make you dizzy and have other side effects that make you less alert. Do not drive or operate machinery until you are sure that you do not have side effects that affect driving or using machines.

[HA765 trade name] contains mannitol

Each tablet contains 29 mg of mannitol, which may have a mild laxative effect.

3. How to take [HA765 trade name]

You should always take [HA765 trade name] exactly as your health care provider has told you. Do not stop taking it without checking with your health care provider. Check with the health care provider if you are not sure.

You can take [HA765 trade name] with food or between meals.

Antacids, calcium supplements, iron supplements, multivitamins

Ask your health care provider for advice if you are taking:

- an antacid (a medicine used for treating indigestion and heartburn)
- calcium supplements
- iron supplements
- multivitamins.

You should take these medicines at least 6 hours before taking [HA765 trade name] or at least 2 hours after taking [HA765 trade name].

Children weighing from at least 3 kg to 25 kg

Children whose HIV infection is resistant to medicines similar to [HA765 trade name] should **not** take [HA765 trade name].

Your health care provider will decide on the correct dose of [HA765 trade name], depending on your weight. Dose recommendations according to weight are presented in table below:

Body weight	Number of tablets of [HA765 trade name] per day
3 kg to less than 6 kg	0.5
6 kg to less than 10 kg	1.5
10 kg to less than 14 kg	2
14 kg to less than 20 kg	2.5
20 kg to less than 25 kg*	3

*The preferred dose of dolutegravir in children and adolescents weighing more than 20 kg is 50 mg once a day taken as a single 50 mg film-coated tablet. However, patients who weigh between 20 and 25 kg who are unable to swallow tablets can take 3 tablets of [HA765 trade name] instead.

The number of tablets given in the table above should be taken once a day. However, the daily dose should be doubled (meaning that you have to take the same number of tablets as indicated in the table above but twice a day) if you are also taking certain other medicines (efavirenz, nevirapine, tipranavir/ritonavir, or rifampicin).

Disperse the tablets in drinking water before taking the dose. Each tablet should be dispersed in a minimum of 10 mL water; the maximum volume of water recommended for dispersion of a dose is 50 mL.

Instructions for use

1. Look up your weight in the table above.
2. Then look for the number of tablets that will be required.
3. Place the required volume of drinking water in a small clean cup and add the required number dolutegravir tablets.
4. Stir gently until the tablets disperse.
5. Drink the entire medicine mixture immediately.
6. Rinse the cup with an additional 10 mL of water, which you should drink.

If you take too many tablets of [HA765 trade name]

If you take too many tablets of [HA765 trade name], contact your health care provider for advice. If possible, show them the [HA765 trade name] pack.

If you forget to take [HA765 trade name]

If you miss a dose of [HA765 trade name], take it as soon as you remember. But if your next dose is due within 4 hours, skip the dose you missed and take the next one at the usual time. Then continue your treatment as before. You must not take a double dose to make up for a missed dose.

Don't stop taking [HA765 trade name] without advice from your health care provider

Take [HA765 trade name] for as long as your health care provider recommends it. Don't stop unless your health care provider advises you to. If you have any further questions on the use of this medicine, ask your health care provider.

4. Possible side effects

Like all medicines, this medicine can cause side effects but not everybody gets them.

Talk to your health care provider if there is any worsening of your health. The changes could be caused by the medicine or the condition getting worse.

Allergic reactions

See a health care provider straightaway if you get an allergic reaction because the health care provider may decide that you should stop taking [HA765 trade name]. The signs of allergic reactions are:

- skin rash
- fever
- tiredness
- swelling under the skin which can involve the face or mouth and cause breathing difficulty
- muscle and joint ache

Very common side effects (which affect more than 1 in 10 people)

headache
diarrhoea
feeling sick (nausea)

Common side effects (which may affect up to 1 in 10 people)

rash, itching (pruritus)
being sick (vomiting), abdominal (belly) pain and discomfort, wind (flatulence)
insomnia, abnormal dreams, depression
dizziness, lack of energy (fatigue)
blood tests showing changes in liver function
blood tests with increased muscle enzymes (creatine kinase) indicating muscle damage

Uncommon side effects (which may affect up to 1 in 100 people)

inflammation of the liver (hepatitis)
suicidal thoughts and behaviours (particularly in patients who have had depression or mental health problems before)
joint and muscle pain

Rare side effect (which may affect up to 1 in 1000 people)

liver failure (signs may include yellowing of the skin and the whites of the eyes or unusually dark urine)
increase in bilirubin (a test of liver function) in your blood

Other possible side effects

People taking medicines for HIV may get other side effects described below.

Infection and inflammation

People with advanced HIV infection (AIDS) have weak immune systems and they are more likely to develop serious infections (opportunistic infections). Such infections may have been 'silent' before starting HIV treatment. After starting treatment, the immune system becomes stronger, and may attack the infections, which can cause symptoms of infection or inflammation. Symptoms usually include fever, headache, stomach ache, and breathing difficulty.

In rare cases, as the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders). The symptoms of autoimmune disorders may develop many months after taking medicine to treat your HIV infection. Symptoms may include palpitations (rapid or irregular heartbeat), tremor, excessive restlessness and movement, weakness beginning in the hands and feet and moving up towards the trunk of the body.

Speak to your health care provider **immediately** if you get any symptoms of infection and inflammation. Do not take other medicines for the infection without checking with your health care provider.

Joint pain, stiffness and bone problems

Some people taking combination therapy for HIV develop a condition called osteonecrosis. It is caused by damage to the bone tissue because of reduced blood supply to the bone. People taking combination therapy for a long time may be more likely to get this condition if they are also taking medicines called corticosteroids, drink alcohol, have a weak immune system, are very weak or are overweight.

Signs of osteonecrosis include joint stiffness, aches and pains in the joints (especially in the hip, knee or shoulder), difficulty moving.

Speak to your health care provider if you notice any of these effects.

Weight, blood lipid and blood glucose effects

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and lifestyle, and in the case of blood lipids sometimes to the HIV medicines themselves. Your health care provider will test for these changes.

Reporting of side effects

If you get any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. If available, you can also report side effects directly through the national reporting system. By reporting side effects you can help improve understanding about the safety of this medicine.

5. How to store [HA765 trade name]

Do not store above 30°C. Store in the original package to protect from moisture. Keep the bottle tightly closed. Avoid excursions above 30°C.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle after “EXP”. The expiry date refers to the last day of that month.

Do not throw away any medicines in wastewater or household waste. Ask your health care provider how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What [HA765 trade name] contains

- The active ingredient is dolutegravir. Each dispersible tablet contains 10 mg dolutegravir.
- The other ingredients of [HA765 trade name] used in the core tablet formulation are mannitol, microcrystalline cellulose, sodium starch glycolate, povidone, silicified microcrystalline cellulose, crospovidone, calcium sulphate dihydrate, strawberry cream flavour, sucralose and sodium stearyl fumarate. The film-coating mixture contains hypromellose, titanium dioxide, macrogol/polyethylene glycol and iron oxide red.

What [HA765 trade name] looks like and contents of the pack

Pink-coloured, capsule-shaped, film-coated tablet debossed with ‘K’ and ‘1’ and separated by a break-line on one side and another break-line on the other side.

[HA765 trade name] is available in white, round, HDPE bottles with polypropylene child resistant closure with pulp and white printed heat seal liner. The bottle may or may not contain a 1g silica gel sachet.

Pack size: 90 tablets.

[HA765 trade name] is available in white, round, HDPE bottles with polypropylene child resistant closure with pulp and white printed heat seal liner. The bottle contains 2 x 1g silica gel sachets.

Pack size: 30 tablets.

Supplier and Manufacturer

Supplier

Macleods Pharmaceuticals Limited
304, Atlanta Arcade
Marol Church road
Andheri (East)
Mumbai – 400 059
India
Tel: +91-22-66762800
Fax: +91-22-28216599
E-mail: exports@macleodspharma.com
vijay@macleodsPharma.com
sjadhav@macleodspharma.com

Manufacturer

Macleods Pharmaceuticals Limited
Block N2, Village Theda
P.O. Lodhimajra
Tehsil Baddi, Dist. Solan
Himachal Pradesh, 174101
India
Tel: +91-1795 661400
Fax: +91-1795 661452
E-mail: jayaramk@macleodspharma.com

Macleods Pharmaceuticals Limited
Unit II, Phase II and IV
Plot No 25-27, Survey No 366
Premier Industrial Estate
Kachigam, Daman, 396 210
India
Tel:+91 260 2241565, +91 22 28216599
Email: jayaramk@macleodspharma.com

Macleods Pharmaceuticals Limited
Plot No.- M-50 to 54-A,
SEZ,Phase II,
Pithampur,
Dist.-Dhar, DHAR,
Madhya Pradesh,
India

For any information about this medicine, contact the supplier.

This leaflet was prepared in January 2022

Section 6 was updated in July 2022

Section 6 was updated in May 2023

Section 6 was updated in September 2023

Detailed information on this medicine is available on the World Health Organization (WHO) website: <https://extranet.who.int/pqweb/medicines>